Medtronic (MDT) Stock Price, Fundamentals & Analysis

What MDT does

Medtronic (MDT) develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: the Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio includes implantable cardiac pacemakers, cardioverter defibrillators, cardiac resynchronization therapy devices, cardiac ablation products, insertable cardiac monitor systems, TYRX products, and remote monitoring software, as well as aortic valves, surgical valve replacement and repair products, endovascular stent grafts, transcatheter pulmonary valves, left atrial appendage exclusion systems, ECMO systems, percutaneous coronary intervention products, percutaneous angioplasty balloons, and endovenous products. Medtronic is part of the S&P 500.

Key numbers explained

• 89.3 USD is the current share price, the amount you would pay for one share today.
• The trailing P/E ratio of 22.2 compares the current price to the last 12 months of earnings per share (4.02 USD); a higher number can mean the market expects faster growth.
• The forward P/E ratio of 13.9 uses expected future earnings, which can make the stock look cheaper if earnings are projected to grow.
• The dividend yield of 3.17% shows the annual dividend as a percentage of the current price; it reflects the cash income you would receive relative to the share price.
• The ex-dividend date of Sep 25, 2026 is the cutoff: you must own the stock before this date to receive the next dividend payment.
• 70% of earnings are paid out as dividends, meaning the company returns a large share of its profit to shareholders.
• The beta of 0.57 suggests the stock tends to move less than the overall market; it is often seen as a lower-volatility holding.
• The 52-week range of 73.31 – 106.33 shows the lowest and highest prices over the past year, and the price is currently -5.2% from one year ago.

Recent news

• Medtronic (MDT) beat Q1 expectations, which led to target hikes, but analysts remain divided on whether the stock deserves a higher valuation.
• Reports highlight the growing surgical devices market and the rising role of AI in healthcare, both areas where Medtronic operates.
• Coverage also references the minimally invasive robotic surgical system market, where Medtronic is benchmarked alongside peers such as Intuitive Surgical (ISRG).

What to watch

• Healthcare policy and reimbursement changes can affect demand for device-based therapies.
• Product launches and regulatory approvals in the cardiovascular and surgical segments may drive future revenue.
• Currency movements matter because Medtronic operates internationally, and the euro-dollar exchange rate can influence reported results.
• Competition from peers such as Regeneron Pharmaceuticals (REGN) and Amgen (AMGN) in adjacent health-tech and biotech spaces can shape market expectations.